San Diego-based Illumina and Redwood City, Calif-based Kartos Therapeutics have established a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will be the first to use TSO 500, which is a research use only (RUO) assay, with peripheral whole blood as a diagnostic sample type.
“With this partnership, Illumina will expand the TruSight Oncology offerings into hematologic malignancies,” says Phil Febbo, MD, chief medical officer of Illumina. “By leveraging our technology and harnessing the expertise at Kartos, we continue to advance Illumina’s commitment to develop standardized, globally distributable tools for precision oncology.”
The initial focus of the collaboration will be the co-development of multiple CDx claims in blood cancers for Kartos’ KRT-232, a potent and selective oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.
“Kartos is dedicated to developing novel, targeted therapeutics that meaningfully improve the lives of patients with cancer,” says Jesse McGreivy, MD, chief executive officer and chief medical officer at Kartos. “This partnership will allow us to capitalize on TSO 500 as we explore the expanded use of KRT-232, which offers a unique mechanism to restore the function of p53, one of the most critical tumor suppressor proteins, resulting in apoptosis of malignant cells across a variety of hematologic and solid tumor types.”
TSO 500 is a research use only comprehensive pan-cancer assay designed to identify 523 known and emerging tumor biomarkers. TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic (IVD) test to the TruSight Oncology product family. This comprehensive tumor profiling assay will have similar chemistry and analytics to TSO 500.